Reason for request

Inclusion

Minor clinical added value in the treatment of locally-advanced basal cell carcinoma not eligible for curative surgery or radiotherapy.

  

  • ODOMZO has marketing authorisation in the treatment of locally-advanced basal cell carcinoma (BCC) not eligible for curative surgery or radiotherapy.
  • The only available data result from a subgroup of a phase II non-comparative study that included two patient profiles: locally-advanced BCC and metastatic BCC. The efficacy results are based on the overall response rate (complete or partial response)
  • ODOMZO is an alternative to ERIVEDGE in this indication. There are no comparative studies.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Contact Us

Évaluation des médicaments